Pharmaceutical Market Attractiveness Increases

BMI View: Japan's pharmaceutical regulatory regime admirably addresses the needs and concerns of the three major industry stakeholders - patients, payers and pharmaceutical companies - and many aspects should be emulated by government agencies in other countries. The major positives include a relatively defined biosimilar approval pathway, free healthcare for the elderly, appreciation of microdose studies, transparent and robust intellectual property rules, and acceptance of orphan drugs. Key drawbacks are the 'drug lag' and frequent price

To read the full article, please choose one of the following options: